Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (CTCL), a heterogeneous group of lymphocytic neoplasms affecting the skin. Early disease is characterized by skin patches or plaques that are based mostly on infiltrates of reactive inflammatory cells with rare malignant T cells present in the affected areas. In advanced-stage disease, that is tumor stages, however, the malignant clone expands and predominates the skin lesion; moreover, it can spread to lymph nodes, blood and eventually viscera. 1 MF is considered an incurable condition, however, due to its indolent nature, early-stage disease can be controlled for years by skin-directed therapies, such as topical corticosteroids, narrow band ultraviolet B or ultraviolet A in combination with psoralen (PUVA), and nitrogen mustard. If the disease becomes refractory to these measures, retinoids/rexinoids, interferon a, histone deacetylase (HDAC) inhibitors and low-dose chemotherapy can be used alone or in combination. Side effects accompanying these therapies range from drug hypersensitivity to increase in the risk of infection or secondary cancer, hematologic toxicity and myelosuppression. Treatment of advanced disease is problematic and often requires aggressive chemotherapy, irradiation or multiple target approaches with responses that are typically not durable; thus, the patients have a poor prognosis. Accordingly, there is a great need to develop novel targeted therapies and combination therapy for the treatment of refractory and advanced MF. 2 The etiology of MF is largely unknown, but numerous signaling pathways have been demonstrated to be involved in disease development and progression. A pathological dysregulation of the janus kinase (Jak)/signal transducer and activators of transcription (Stat) signaling axis has been detected in the majority of patients as well as a constitutive activation of other transcription factors such as NF-kB, c-Fos, c-Jun or c-Myc. Abnormal expression of cytokines interleukin (IL)-5, IL-6, IL-7, and IL-13 and angiogenetic factors is also a characteristic feature of MF.
3,1 Recently, we discovered that cyclooxygenase-2 (COX-2) is aberrantly expressed in situ in advanced MF. Importantly, the aberrant COX-2 expression is associated with disease progression suggesting a role in the malignant transformation. 4 In normal cells, COX-2 is an inducible key factor in prostaglandin synthesis and mediates inflammation by increased levels of prostaglandin. Ectopic expression of COX-2 and its downstream partner microsomal prostaglandin E synthase-1 (mPGES1) has been implicated in the pathogenesis of several cancer types, and the resulting production of prostaglandin E 2 (PGE 2 ) is known to sustain cancer progression by promotion of angiogenesis, invasion and metastasis. 5, 6 In advanced MF, the aberrant COX-2 drives a spontaneous, high production of PGE 2 . In this respect it is important to note that PGE 2 functions as growth factor for malignant T cells, and inhibitors of COX-2 and mPGES1 strongly inhibit PGE 2 -mediated proliferation of malignant T cells. 4 In particular, a COX-2 inhibitor already in clinical use for inflammatory diseases, celecoxib (Celebra, Pfizer, Ballerup, Denmark), is a highly potent inhibitor of the spontaneous proliferation of malignant T cells in vitro. 4 This study was undertaken to determine if celecoxib has the potential to inhibit tumor formation and growth also in vivo. To this end, we took advantage of a xeno-transplant mouse model of advanced MF. 7 Accordingly, COX-2-positive MyLa cells were inoculated subcutaneously into immune-deficient NOD. Cg-PrkdcscidB2mtm1Unc/J (NOD/SCID-B2m À/À ) mice (The Jackson Laboratory, Bar Harbor, ME, USA). This mouse strain is deficient for major histocompatibility complex class I, B and T cells, as well as C-5, and has low natural killer cell activity. In 80-90% of the mice, tumor formation is detected on average 14 days after inoculation. 7 In the first series of experiments, we evaluated the effect of celecoxib on implantation of MF cells. Accordingly, we initiated a 'prevention' study (Study 1) using 20 animals that were inoculated with 1 Â 10 6 MyLa cells into each flank. The mice were divided into two groups of 10 animals each, which were treated with daily intraperitoneal injections of 10 mg/g body weight celecoxib or vehicle (10% human serum, 10% dimethylsulfoxide), starting from the day of tumor cell injection. After 21 days, the experiment was terminated and . Median survival in celecoxib (9 animals) and control group (11 animals) was 47 and 32 days, respectively. Po0.0001 (log-rank test). Sections were stained with a mouse monoclonal antibody against Ki-67 (clone MIB-1, DAKO, Glostrup, Denmark), as previously described. In brief, paraffin-embedded tissue was cut in 4 mm thick sections and processed for immunohistochemical staining. Antigen retrieval by microwaving slides submerged in EDTA buffer (pH 9) was used before immunostaining of sections for Ki-67 with peroxidase-based Envision (DAKO) and sections were counterstained with light green. Magnifications (a-d): 2.5Â. a1-a3, b1-b3, c1-c3 and d1-d3 show selected areas through the tumor in a 10 Â magnification.
Letters to the Editor tumor number and load in each group was determined ( Figure 1 ). Preventive celecoxib treatment proved very effective: it not only reduced the number of tumors from 16 in the control group to 10 in the treatment group but also reduced the mean tumor weight from 120.2 to 39.85 mg in the celecoxib-treated group. The difference proved statistically significant (t-test, Po0.05). Moreover, five animals (50%) of the treated group did not develop any tumors, whereas there were only two animals (20%) in the control group, in which tumors failed to establish. These findings suggest that celecoxib inhibits establishment of tumors and/or tumor growth, suggesting that celecoxib could have a potential role in tumor prevention in analogy with the preventive role of selective and broad COX-2 inhibitors (such as aspirin) in colon cancer. Next, we addressed the question whether celecoxib is also able to inhibit growth of already established tumors, in a 'treatment' study in the same tumor model (Study 2). To this end, treatment was delayed until tumors were clearly palpable. Of a total of 24 mice that were injected with MyLa cells, 20 developed tumors and were randomly allocated for later treatment with celecoxib at 10 mg/g body weight or vehicle and subjected to daily intraperitoneal injections for 60 days or until the tumors had reached their maximal allowed size (12 mm in the largest diameter). Figure 2 depicts the Kaplan-Meier plots of the celecoxib-treated animals and the control group. On day 38 after initiation of treatment, 78% of the celecoxib-treated animals were still alive, whereas all of the control mice had to be killed, their tumors having reached the maximal size. On day 60, when the study was terminated, the tumors of 33% of the celecoxib-treated mice (three animals) had not reached the maximal size (Table 1 ). The median survival was 47 days in the celecoxib group and 32 days in the control group (log-rank test, Po0.0001), indicating that treatment with celecoxib inhibited growth of established tumors in vivo. Discontinuation of the treatment in the three mice with submaximal tumors after day 60, resulted in all three mice in the tumor growth acceleration that almost matched the growth curves in the control, never treated mice (data not shown).
As celecoxib induces cell growth arrest in vitro, we compared tissue sections of tumors from celecoxib and control mice from the intervention study with respect to expression of the proliferation marker Ki-67. Tumors from the celecoxib-treated animals exhibited significantly lower levels of proliferation as judged from weaker Ki-67 staining. In particular, the hyperproliferative zones at the tumor edge were significantly thinner in celecoxib-treated animals ( Figure 3) . Similarly, lower proliferative activity was seen in the inner zones of tumors in celecoxibtreated mice when compared with tumors from control mice (Figure 3 ). In contrast, no significant difference in the level of apoptosis was observed between celecoxib-treated and control mice (data not shown), indicating that the inhibition of tumor growth caused by celecoxib in vivo was caused rather by an inhibition of malignant T-cell proliferation than their apoptosis. This conclusion is in keeping with our observations that celecoxib primarily induces MF cell growth arrest, but not apoptosis in vitro, 4 and that MF tumors display, after discontinuation of celecoxib treatment, an accelerated growth in vivo, as mentioned above.
In summary, we show that the COX-2 inhibitor celecoxib inhibits tumor growth in vivo in an experimental xenograft mouse model of advanced MF. In fact, the effect of celecoxib appeared to be more pronounced than that of vorinostat (an HDAC inhibitor recently approved by the Food and Drug Administration for treatment of refractory CTCL) when used in the same xenotransplantation model. 2 Given an ectopic expression of COX-2 in malignant T cells in patients with advanced MF, our findings suggest that COX-2 is a novel therapeutic target in advanced MF. Because celecoxib is already approved for several non-malignant diseases and displays limited side effects, 8 this drug could provide a novel, nonaggressive option for treatment of patients with advanced MF. However, COX-2 inhibition appears to trigger growth arrest of MF cells rather than apoptosis, which may adversely affect its efficacy as a single agent. In keeping with this hypothesis, multiple signaling pathways are believed to confer to the malignant transformation in MF. Investigations are now in progress to study the interaction and efficacy of celecoxib in combination with already existing as well as experimental therapies.
